Assessment of Hazard Ratios in Oncology Clinical Trials Terminated Early for Superiority-Reference-Cited by-同舟云学术

Assessment of Hazard Ratios in Oncology Clinical Trials Terminated Early for Superiority

Published:2020-06-23 Issue:6 Volume:3 Page:e208633
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Shimura Masashi¹,Nomura Shogo²,Wakabayashi Masashi²,Maruo Kazushi³,Gosho Masahiko³

Affiliation:

1. Data Science Department, Taiho Pharmaceutical Co, Ltd, Tokyo, Japan

2. Center for Research and Administration and Support, Biostatistics Division, National Cancer Center, Chiba, Japan

3. Department of Biostatistics, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2767516/shimura_2020_oi_200366.pdf

Reference25 articles.

1. Comparison of conditional bias-adjusted estimators for interim analysis in clinical trials with survival data.;Shimura;Stat Med,2017

2. Conditional estimation following a group sequential clinical trial.;Troendle;Commun Stat Theory Methods,1999

3. Conditional estimation using prior information in 2-stage group sequential designs assuming asymptotic normality when the trial terminated early.;Shimura;Pharm Stat,2018

4. Overestimation of the effect size in group sequential trials.;Zhang;Clin Cancer Res,2012

5. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.;Moher;Ann Intern Med,2009

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Challenges of estimating treatment effects after a positive interim analysis;European Journal of Cancer;2024-09

2. Challenges of Estimating Treatment Effects after a Positive Interim Analysis;2024

3. Point estimation for adaptive trial designs II: Practical considerations and guidance;Statistics in Medicine;2023-04-05